Novo will begin selling the tablet in the United States in early January, the company announced Monday.
The pill is key to the strategy to compete with Lilly, which has said its own oral obesity drug could be approved by March. This would give Novo, owner of Ozempic, an advantage of only a few months.
After this announcement, the revenues of the pharmaceutical group’s shares traded in the United States (ADR) increased by more than 8% on the market. after market. However, they have accumulated a decline of 44% this year, reflecting investors’ concern about the company’s position in the market.
Novo has struggled to compete in the obesity market – a segment it significantly helped create. Its blockbuster drug, Wegovy, lost ground to Lilly’s Zepbound after a comparative study showed Zepbound could help people lose more weight. Additionally, Novo’s next-generation injection, CagriSema, failed to produce the weight loss the company promised in its studies.
About The Author
